Last reviewed · How we verify
Berberine plus Bezafibrate — Competitive Intelligence Brief
phase 3
Combination therapy: alkaloid + fibrate
AMPK (berberine); PPAR-α/γ (bezafibrate)
Cardiovascular, Metabolic/Endocrinology
Small molecule
Live · refreshed every 30 min
Target snapshot
Berberine plus Bezafibrate (Berberine plus Bezafibrate) — University of Guadalajara. Berberine and bezafibrate work together to improve lipid metabolism and glucose control through alkaloid and fibrate mechanisms.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Berberine plus Bezafibrate TARGET | Berberine plus Bezafibrate | University of Guadalajara | phase 3 | Combination therapy: alkaloid + fibrate | AMPK (berberine); PPAR-α/γ (bezafibrate) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Combination therapy: alkaloid + fibrate class)
- University of Guadalajara · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Berberine plus Bezafibrate CI watch — RSS
- Berberine plus Bezafibrate CI watch — Atom
- Berberine plus Bezafibrate CI watch — JSON
- Berberine plus Bezafibrate alone — RSS
- Whole Combination therapy: alkaloid + fibrate class — RSS
Cite this brief
Drug Landscape (2026). Berberine plus Bezafibrate — Competitive Intelligence Brief. https://druglandscape.com/ci/berberine-plus-bezafibrate. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing